Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00235885 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

A Phase 3 study, sponsored by Abbott.

Completed
Registry status
Phase 3
Development phase
445
Enrollment target

NCT00235885: Completed Phase 3 study, sponsored by Abbott.

NCT00235885 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 445 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00235885, a Phase 3 study, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 3
Development phase
445 participants
Enrollment target

Study Summary

The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies

Interventions

  • DRUG adalimumab

Trial Details

FieldValue
Enrollment Target 445 participants
Start Date 2005-07
Phase Phase 3
Abbott

181 total trials

What the finished NCT00235885 record still lists

NCT00235885 is an interventional study that assigns participants to a tested intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).

The record links to 0 conditions, and to 1 intervention - of which adalimumab is the first listed.

NCT00235885 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00235885 about?

NCT00235885 is a clinical study titled "Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)". The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies

What is the current status of trial NCT00235885?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2005-07.

What interventions are being tested in trial NCT00235885?

The interventions under investigation include: adalimumab (DRUG).

Who is sponsoring clinical trial NCT00235885?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00235885's enrollment target sits among peer trials

445 864th of 2000 higher than 1,137 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01280994 · 445 participants · Phase 2

    Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

  • NCT03504800 · 445 participants

    OCT in Diagnosis of Irregular Corneas

  • NCT04751435 · 445 participants · NA

    Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

  • NCT06348394 · 444 participants · NA

    Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00235885, the US trial registry maintained by the National Library of Medicine. NCT00235885 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.